[Malignant lymphoma of the testis]

Area of Science:

• Oncology
• Hematology
• Urologic Oncology

Context:

• Non-Hodgkin's lymphoma (NHL) of the testis is a rare malignancy, accounting for approximately 1.8% of adult testicular tumors.
• Orchidectomy is a primary diagnostic and initial treatment step for suspected testicular lymphoma.
• Understanding treatment outcomes and prognostic factors is crucial for managing this rare cancer.

Purpose:

• To report on the clinical characteristics, treatment modalities, and outcomes of ten patients with histologically confirmed testicular non-Hodgkin's lymphoma.
• To analyze treatment responses, relapse patterns, and survival rates in patients treated with chemotherapy, radiotherapy, or both post-orchidectomy.
• To highlight the incidence of central nervous system (CNS) involvement in testicular lymphoma.

Summary:

• Ten cases of testicular non-Hodgkin's lymphoma (NHL) were reviewed, including diffuse large cell (5), immunoblastic (4), and diffuse small cell (1) subtypes.
• Patients aged a mean of 56 years; 5 had early-stage (IE/IIE) and 5 had advanced-stage (IV) disease.
• Treatment involved chemotherapy with subdiaphragmatic irradiation (7 patients) or radiotherapy alone (2 patients). Relapse occurred in 4 patients, with CNS involvement noted in 5 cases. Five patients achieved long-term remission (18-80 months).

Impact:

• This case series provides insights into the management and prognosis of testicular lymphoma, a rare but aggressive malignancy.
• Findings emphasize the importance of multimodal therapy and highlight the risk of central nervous system relapse.
• The study contributes to the limited literature on testicular lymphoma, aiding in clinical decision-making and future research directions.